Data

AYAPK Pharmacokinetics and Pharmacodynamics of Doxorubicin in Children, Adolescents and young adults with Newly Diagnosed Osteosarcoma, Ewing Family of Tumours and Hodgkin Lymphoma A Multi-Institutional Cross-Discipline Non-Therapeutic Study

Australia and New Zealand Sarcoma Association(ANZSA)

Dataset description

The dataset contains individual patient data for 66 participants. This includes data chemotherapy drug dosage, drug dose modification, site of disease and extent, disease progression, medical history and adverse events.
Click to explore relationships graph

Subjects

Chemotherapy |

Related Study

Pharmacokinetics and Pharmacodynamics of Doxorubicin in Children, Adolescents and young adults with Newly Diagnosed Osteosarcoma, Ewing Family of Tumours and Hodgkin Lymphoma A Multi-Institutional Cross-Discipline Non-Therapeutic Study

Brief Summary

Currently the doses of medication given to treat cancer are generally determined by a simple body surface area (BSA) calculation based on weight and height. However, physiological differences between individuals may affect the way cancer drugs are processed by the body, potentially leading to variable dose levels in the body, and differences in toxicity and efficacy between individuals. This study is looking at the way the body processes the drug doxorubicin (this is called pharmacokinetics and pharmacodynamics), to see if gender, stage of puberty, or body composition may impact the effectiveness or toxicity of doxorubicin. The study focuses on osteosarcoma, Ewing family of tumours and Hodgkin lymphoma because there is some evidence that there may be a difference between males and females in the response to chemotherapy for these cancers. These cancers mainly affect young people, many of whom are undergoing the physical changes of puberty, which are different for males and females.

Inclusion Criteria

  • Newly diagnosed with osteosarcoma, Ewing family of tumours or Hodgkin lymphoma; aged between 1 year and 40 years of age; planned treatment involves a standard doxorubicin-containing regimen; written informed consent from patient and/or patient’s parent or legal guardian

Study Type

  • Interventional

Ethics Approval

The data-sharing statement for this study is currently unavailable.